Sodium Tungstate in Obesity (TROTA-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00555074
Recruitment Status : Completed
First Posted : November 7, 2007
Last Update Posted : March 31, 2010
Fundacio Clinic
Information provided by:
Hospital Clinic of Barcelona

Brief Summary:
The purpose of this study is to compare the efficacy and safety of sodium tungstate versus placebo in patients with obesity (grade I and II).

Condition or disease Intervention/treatment Phase
Obesity Drug: Sodium Tungstate Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Oral Sodium Tungstate (200 mg/Day)on Weight Loss in Subjects With Grade I-II Obesity
Study Start Date : November 2007
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Weight Control
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Sodium Tungstate
Drug: Sodium Tungstate
Sodium Tungstate, 200 mg BID, oral route during 6 weeks
Placebo Comparator: 2 Drug: Placebo
Placebo, BID, oral route during 6 weeks

Primary Outcome Measures :
  1. weight loss [ Time Frame: six weeks ]

Secondary Outcome Measures :
  1. changes in lipids [ Time Frame: 6 weeks ]
  2. changes in caloric intake and in hungry sensation [ Time Frame: 6 weeks ]
  3. resting metabolic rate [ Time Frame: 6 weeks ]
  4. changes in body composition [ Time Frame: 6 weeks ]
  5. adverse events [ Time Frame: 6 weeks ]
  6. changes in hormonal parameters [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • BMI: 30-39.9 Kg/m2
  • In case of male gender, 18 to 65 years old
  • In case of female gender, diagnosis of menopause
  • Body weight changes < 3 kg in the last 3 months
  • In case of arterial hypertension or dyslipemia, no changes in dose in the last 2 months

Exclusion criteria:

  • In case of female gender, absence of menopause
  • Evidence of secondary causes of obesity
  • Diabetes, type II
  • Concomitant treatment with drugs affecting body weight
  • Previous surgical intervention of obesity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00555074

Hospiral Clinic de Barcelona
Barcelona, Spain, 08036
Sponsors and Collaborators
Hospital Clinic of Barcelona
Fundacio Clinic
Principal Investigator: Josep Vidal, MD Hospital Clinic of Barcelona

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Josep Vidal, Hospital Clinic Barcelona Identifier: NCT00555074     History of Changes
Other Study ID Numbers: TROTA-1
EudraCT: 2006-000567-28
First Posted: November 7, 2007    Key Record Dates
Last Update Posted: March 31, 2010
Last Verified: May 2008

Additional relevant MeSH terms:
Nutrition Disorders
Body Weight
Signs and Symptoms